Eli Lilly (LLY) announced that its KRAS G12C inhibitor, olomorasib, has received FDA Breakthrough Therapy designation for advanced pancreatic cancer in patients with the specific KRAS G12C mutation. This designation is a major regulatory fast-track, signaling the drug's potential to offer substantial improvement over existing treatments for this notoriously difficult-to-treat cancer.

The company also entered a new clinical trial collaboration with Amplia...